193 related articles for article (PubMed ID: 34504191)
1. DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis.
Chashchina A; Märklin M; Hinterleitner C; Salih HR; Heitmann JS; Klimovich B
Sci Rep; 2021 Sep; 11(1):18012. PubMed ID: 34504191
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
[TBL] [Abstract][Full Text] [Related]
3. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+
Jin Z; Ye W; Lan T; Zhao Y; Liu X; Chen J; Lai J; Chen S; Zhong X; Wu X
Biomed Res Int; 2020; 2020():4612952. PubMed ID: 32802845
[TBL] [Abstract][Full Text] [Related]
7. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
8. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
9. The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation.
Kraus AK; Chen J; Edenhofer I; Ravens I; Gaspert A; Cippà PE; Mueller S; Wuthrich RP; Segerer S; Bernhardt G; Fehr T
PLoS One; 2016; 11(2):e0147951. PubMed ID: 26840537
[TBL] [Abstract][Full Text] [Related]
10. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
Kearney CJ; Ramsbottom KM; Voskoboinik I; Darcy PK; Oliaro J
Oncoimmunology; 2016 Aug; 5(8):e1196308. PubMed ID: 27622064
[TBL] [Abstract][Full Text] [Related]
11. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands.
Tahara-Hanaoka S; Miyamoto A; Hara A; Honda S; Shibuya K; Shibuya A
Biochem Biophys Res Commun; 2005 Apr; 329(3):996-1000. PubMed ID: 15752754
[TBL] [Abstract][Full Text] [Related]
13. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
[TBL] [Abstract][Full Text] [Related]
14. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
15. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia.
Tamura H; Dan K; Tamada K; Nakamura K; Shioi Y; Hyodo H; Wang SD; Dong H; Chen L; Ogata K
Clin Cancer Res; 2005 Aug; 11(16):5708-17. PubMed ID: 16115907
[TBL] [Abstract][Full Text] [Related]
16. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.
Wang H; Qi J; Zhang S; Li Y; Tan S; Gao GF
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):988-996. PubMed ID: 30591568
[TBL] [Abstract][Full Text] [Related]
17. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.
Volk A; Li J; Xin J; You D; Zhang J; Liu X; Xiao Y; Breslin P; Li Z; Wei W; Schmidt R; Li X; Zhang Z; Kuo PC; Nand S; Zhang J; Chen J; Zhang J
J Exp Med; 2014 Jun; 211(6):1093-108. PubMed ID: 24842373
[TBL] [Abstract][Full Text] [Related]
18. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
20. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
